CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital)

抗CD19/CD20嵌合抗原受体T细胞疗法

Report date: 2024/11/22 20:00:28

Base Information

Drug NameCD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsAnti-CD19Anti-CD20

TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaPending

Originator CompaniesHenan Provincial Cancer Hospital

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesHenan Provincial Cancer Hospital

Active IndicationsN/A

Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A